Purpose {#sec1}
=======

Modern high-dose-rate brachytherapy (HDR-BT) of prostate cancer enables the delivery of a very high single or multiple dose of radiation to the target volume (e.g. prostate capsule) and, at the same time, preventing the organs at risk from unnecessary radiation (e.g. urethra and rectal wall) \[[@cit0001]--[@cit0003]\]. The 3D reconstruction of ultrasound image series is used for prospective treatment planning which is based on dose volume parameters. There are certain dose volume constraints for target coverage and dose limits in OARs \[[@cit0004], [@cit0005]\]. Furthermore, there is some evidence that dose values in treated volume are dependent on different factors such as prostate volume, location of urethra and number of inserted applicators \[[@cit0006]--[@cit0009]\]. Amongst the large number of prostate cancer patients there is a group that is suitable for combined treatment of external beam radiotherapy (EBRT) and preceded or followed by HDR-BT. The feasibility and efficacy of such approach in localized prostate cancer has been already proven \[[@cit0004], [@cit0010], [@cit0011]\]. Combination of EBRT with HDR-BT boost is found to be effective and related to comparatively low incidence of side effects \[[@cit0004], [@cit0011]--[@cit0013]\]. It was noticed during clinical practice in the department that the final outcome of consecutive HDR-BT treatment plans optimization was connected, to some extent, to e.g. prostate volume or number of needles used for the implant. A question has been posed about the nature of this observation and whether it could be related to other prostate cancer prognostic factors.

The aim of this study was to determine the relation between dose-volume parameters (in the prostate and OARs) obtained from HDR-BT treatment plans and particular prostate cancer prognostic factors along with prostate volume and the number of implanted needles. In the study, morbidity was not taken into consideration.

Material and methods {#sec2}
====================

High-dose-rate brachytherapy for prostate cancer was introduced to the Brachytherapy Department in Greater Poland Cancer Centre in July 2006. Since that time till July 2007, the number of 190 patients (age 52-81, median 68 years) with localized prostate cancer (T~1-30~N~0~M~0~) has been treated with interstitial Iridium-192 (^192^I) HDR-BT ([Table 1](#t0001){ref-type="table"}). All patients were treated with combination of external beam radiotherapy. According to the institutional protocol, dose of 50 Gy (dose fraction of 2 Gy) was initially administered to the prostate and pelvis (in case of high risk of nodal involvement). Intensity modulated radiotherapy (IMRT) or 3-dimentional conformal radiotherapy (3DCRT) techniques were used. After 2-4 weeks patients were admitted for 48 hour in-ward stay to be boosted with HDR-BT. To all men, dose of 15 Gy boost to CTV1 (encompassed by prostate capsule) was administered in a single fraction. Examples of treatment procedure are presented in [Figs. 1](#f0001){ref-type="fig"}--[2](#f0002){ref-type="fig"}.

###### 

Patients characteristics (n = 190)

  --------------------------------------------------------------------------------------------
  Characteristics                                 All cases (n = 190)
  ----------------------------------------------- --------------------------------------------
  Age, median (range)                             68 (52-81)

  T stage\                                        \
   T1\                                            22.6% (43)\
   T2\                                            69.0% (131)\
   T3                                             8.4% (16)

  i-PSA\                                          \
   \< 10 ng/ml\                                   36.3% (69)\
   10-20 ng/ml\                                   30.0% (57)\
   \> 20 ng/ml                                    33.7% (63)

  Gleason score\                                  \
   2-6\                                           52.1% (99)\
   7\                                             28.4% (54)\
   8-10\                                          16.3% (31)\
   ns                                             3.2% (6)

  Risk groups\                                    \
   low \[T1-2a, GS ≤ 6, i-PSA ≤ 10\]\             17.9% (34)\
   intermediate \[T2b-c, GS = 7, i-PSA 10-20\]\   37.4% (74)\
   high \[T3, GS ≥ 8, i-PSA ≥ 20\]                44.7% (85)

  Prostate volume, cc, median (range)             25 (9-87)[\*](#tf1-1){ref-type="table-fn"}

  Hormonal therapy\                               \
   yes\                                           66.8% (127)\
   no                                             33.2% (63)
  --------------------------------------------------------------------------------------------

in 3 cases treated volume exceeded recommended 60 cc and achieved 81 up to 87 cc

Abbreviations: i-PSA -- initial level of prostate specific antigen, ns -- not specified, GS -- Gleason score

![SWIFT system (Nucletron^®^) for HDR brachytherapy of prostate cancer](JCB-1-12015-g001){#f0001}

![Example of HDR brachytherapy of prostate cancer (SWIFT^®^); templates, steel needles and connection cables visible](JCB-1-12015-g002){#f0002}

Prognostic factors such as age, staging, Gleason score, initial PSA level, and prostate volume (based on transrectal ultrasound examination) were assessed before the procedure.

Real-time intraoperative treatment planning software (Nucletron B. V., SWIFT^®^) was used in order to incorporate blind inverse planning optimization and is complementary to microSelectron^®^ HDR remote afterloader (Nucletron B. V., Veenendaal, The Netherlands) ([Fig. 2](#f0002){ref-type="fig"}). This system enables the operator to acquire series of ultrasound images, offers real-time visualization of the needle placement, display 2D and 3D volumes for 3D planning as well as gives the opportunity to optimize a conformal treatment plan and to generate the dose volume parameters with dose volume histogram (DVH). Dose volume parameters were determined as follows: D~min~ (minimal dose), D~max~ (maximal dose), D~mean~ (mean dose), D~90~ (the percentage of reference dose \[D~ref~\] delivered to 90% of treated volume), V~100,~ V~150,~ V~200~ (the volume of the target receiving 100%, 150% and 200% of reference dose, respectively) for prostate; D~min~, D~max~, D~mean~, D~10~ (the percentage of the reference dose delivered to 10% of OAR volume) and V~100~ for urethra and rectum (OARs), respectively ([Fig. 3](#f0003){ref-type="fig"}).

![Treatment plan, dose volume parameters and dose volume histogram (DVH) from SWIFT^®^ planning system](JCB-1-12015-g003){#f0003}

As it is accepted in our department, the aim of each good quality implant is to deliver more than 90% of prescribed dose to at least 90% of target volume (D~90~ \> 90%). Dose volume limitation of OARs such as urethral D~10~ \< 120% and rectal D~10~ \< 75% were taken into account during treatment plan optimization. Once the data was collected, the dose volume parameters were correlated with prognostic factors, prostate volume and number of needles used for particular implant.

The correlation was done in six ways ([Table 2](#t0002){ref-type="table"}). Firstly, prognostic factors were correlated with actual prognostic factors, followed by dose-volume parameters for the prostate, urethra and anterior rectal wall, respectively. Secondly, prostatic dose-volume parameters were correlated with dose-volume parameters for urethra and, separately, for the anterior rectal wall. Statistical analysis was prepared with the Spearman Correlation Index. All findings obtained from the calculation were taken into consideration only in case of attaining significant level of p-value \< 0.05 ([Table 3](#t0003){ref-type="table"}).

###### 

Investigated parameters and the way of correlation

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Prognostic factors                                                                                                                                                                                                                                                                                     DVH parameters   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------- ---------------- ------------------------
  Age                                                                                                                                                                                                                                                                                        Prostatic   Urethral         Rectal (anterior wall)

  T stage                                                                                                                                                                                                                                                                                    D~min~      D~min~           D~min~

  i-PSA                                                                                                                                                                                                                                                                                      D~max~      D~max~           D~max~

  Gleason score\                                                                                                                                                                                                                                                                             D~mean~     D~mean~          D~mean~
     other                                                                                                                                                                                                                                                                                                                

  D~90~                                                                                                                                                                                                                                                                                      D~10~       D~10~            

  Volume of prostate gland                                                                                                                                                                                                                                                                   V~100~      V~100~           V~100~

  Number of needles                                                                                                                                                                                                                                                                          V~150~\                      
                                                                                                                                                                                                                                                                                             V~200~                       

  The way of correlation \[Spearman rank correlation coefficient; significance level: p-value \< 0.05\]                                                                                                                                                                                                                   

  Prognostic factors vs. prognostic factorsPrognostic factors vs. prostatic DVH parametersPrognostic factors vs. urethral DVH parametersPrognostic factors vs. rectal DVH parametersProstatic DVH parameters vs. urethral DVH parametersProstatic DVH parameters vs. rectal DVH parameters                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: DVH -- dose volume histogram, T -- tumor stage according to TNM classification, i-PSA -- initial level of prostate specific antigen (before treatment), Dmin -- minimal dose in treated volume, D~max~ -- maximal dose in treated volume, D~m~ -- mean dose, D~90~ -- the percentage of prescribed dose delivered to 90% of treated volume, D~10~ -- the percentage of the organ at risk receiving 10% of prescribed dose; V~100~, V~150~, V~200~ -- the percentage of treated volume receiving 100, 150 and 200% of prescribed dose, respectively

###### 

Statistical analysis results (Spearman rank correlation coefficient; significance level: p-value \< 0.05).

                                                      Prognostic factors   DVH parameters for prostate gland (PTV)   DVH parameters for urethra (OAR)   DVH parameters for rectum (OAR)                                                                                                                                                                                                           
  -------------------------------------- ------------ -------------------- ----------------------------------------- ---------------------------------- --------------------------------- ------------- ------------- ------------- ------- ------- ------------- ------- ------- --------- ------------- ------------- ------------- ------------- ------------- ------- ------- ------- ------- -------
                                         **Age**      x                    **--0.188**                                                                                                                                                                                                      0.177                       0.222                                                                     
                                         **T**        **--0.188**          x                                                                            0.223                             0.155                                                     0.167         0.165                                                                                                                           
  **Prognostic factors**                 **GS**                                                                                                         x                                 0.114         **--0.151**                                                                                                                                                                               
                                         **i-PSA**    0.223                0.114                                     x                                                                                                                                                                                                                                                                            
                                         **Vol**      0.155                **--0.151**                                                                                                                  x             0.679         0.311           **--0.144**   0.391   0.378             **--0.263**   0.281         **--0.199**   0.393                       0.396                           
                                         **NN**                                                                                                                                                         0.679         x             0.348                         0.455   0.469             --0.223       0.194         **--0.264**   0.238                       0.236                           
                                                                                                                                                                                                                                                                                                                                                                                                  
                                         **D~min~**                                                                                                                                       0.311         0.348         x                             0.739         0.658           --0.212   0.165         --0.194       0.192                       0.223                                         
                                         **D~max~**                                                                                                                                                                                 x       0.640                                 0.525     0.267                       0.182         0.199         0.154         0.240           0.218   0.216   0.238
                                         **D~m~**                                                                                                                                         **-0.144**                                0.640                                 0.664   0.925                   0.241                       0.256         **--0.203**   0.220   0.177   0.214   0.220   0.250
                                         **D~90~**    0.167                                                                                                                               0.391         0.455         0.739                         x                                       0.235         **--0.365**   0.223         **--0.192**   0.246                                         
  **DVH parameter for prostate gland**   **V~100~**   0.165                                                                                                                               0.378         0.469         0.658                                       x                         0.193         **--0.353**   0.166         **--0.218**   0.187                                         
                                         **V~150~**                                                                                                                                                                                 0.664                                 x                               0.294         **--0.242**   0.260         **--0.349**                                   
                                         **V~200~**                                                                                                                                       **--0.263**   **--0.223**   **--0.212**   0.525   0.925                                 x                       0.313         **--0.221**   0.260         **--0.303**   0.179   0.165   0.175   0.188   0.238

Abbreviations: DVH -- dose volume histogram, PTV -- planning target volume, OAR -- organ at risk, T -- tumor stage according to TNM classification, GS -- Gleason score, i-PSA -- initial level of prostate specific antigen (before treatment), Vol -- volume of prostate gland assessed before treatment, NN -- number of needles used for implant, Dmin -- minimal dose in treated volume, D~max~ -- maximal dose, D~m~ -- mean dose, D~90~ -- the percentage of prescribed dose delivered to 90% of treated volume (PTV), D~10~ -- the percentage of the organ at risk receiving 10% of prescribed dose; V~100~, V~150~, V~200~ -- the percentage of treated volume receiving 100, 150 and 200% of prescribed dose, respectively; blank spaces -- lack of statistically significant correlation

Results {#sec3}
=======

The mean value of D~90~ was calculated to be 13.69 Gy which stands for 91.3% of D~ref~ (range 65.9-102.8%, median 91.8%). The mean urethral and rectal D~10~ was 18.27 Gy = 121.8% D~ref~ (range 78.8-152.9%, median 122.4%) and 9.96 Gy = 66.4% D~ref~ (range 37.4-98.1%, median 66.7%), respectively. The mean treated volume was 25 cc (range 9-87 cc).

Statistical analysis of prostate cancer prognostic factors correlated with dose-volume parameters, revealed as a set of results and pointed below.

Patient's age was found to be related to increase urethral D~max~ and D~10~. This finding can be explained with another statistically significant relation between age and decreased T stage -- the older the patient, the lower T stage is likely to be assessed. On the other hand, higher T stage (in relatively younger patients) is related to higher level of i-PSA and larger volume of prostate. The T stage is also proportional to final values of prostatic D~90~ and V~100~.

As for Gleason score (GS), it was found to be directly proportional only to i-PSA and inversely proportional to prostate volume, with no relation to any of dose volume parameters. As it can be derived from the above, i-PSA is proved to be related to T stage and Gleason score. No relation to any of dose-volume parameters was identified for i-PSA.

Furthermore, the larger the prostate volume and the higher T stage to be assessed, the lower GS can be determined and larger number of needles is required for implantation. Moreover, large prostate volume results in higher values of prostatic D~min~, D~90~ and V~100~ and lower values of prostatic Dmean and V~200~. Prostate volume also exerts its impact on urethral parameters. Urethral D~min~, D~mean~ and V~100~ are directly proportional and D~max~ is inversely proportional to prostatic volume. It is quite clear that the number of needles used for an implant is directly related to the prostate volume. For a particular implant, the number of 14 needles was used in average (range 7-18). Correlation of the number of needles with prostatic and urethral dose-volume parameters resulted in the same findings such as the prostate volume. One could notice that no relationship was found between prognostic factors and dose volume parameters for rectal wall. All the collected data were secondarily analyzed paying particular attention to correlation between DVH parameters for prostate gland and OARs. As it turned out, the prostatic D~90~ and V~100~ are inversely proportional to urethral D~10~ and D~max~ and directly proportional to urethral D~min~, D~mean~ and V~100~ ([Table 4](#t0004){ref-type="table"}). In a real situation the better target coverage is achieved, the lower D~10~ and maximal dose to the urethra is delivered. In the study, prostatic D~90~ and V~100~ did not associate with rectal DVH parameters. For prostatic V~200~, it was found to be directly proportional to urethral D~max~ and D~10~, rectal D~min~, D~max~, D~mean~, D~10~ and V~200~. Moreover, higher values of prostatic V~200~ were related to lower urethral D~mean~ and V~100~.

###### 

Correlation results divided into two groups of directly or inversely proportional relationships between investigated parameters

  -----------------------------------------------------------------------------------------------
  Parameter   Direct proportion                                           Inverse proportion
  ----------- ----------------------------------------------------------- -----------------------
  Age\        UD~10~, UD~max~\                                            T\
  T\          i-PSA, Vol, PD~90~, PV~100~\                                Age\
  i-PSA\      i-PSA\                                                      Vol\
  GS\         T, GS\                                                      \
  Vol\        T, NN, PD~min~, PD~90~, PV~100~, UD~min~, UD~m~, UV~100~\   GS, PV~200~, UD~max~\
  NN          Vol, PD~min~, PD~90~, PV~100~, UD~min~, UD~m~, UV~100~      \

  PD~90~\     UD~min~, UD~m~, UV~100~\                                    UD~10~, UD~max~\
  PV~100~\    UD~min~, UD~m~, UV~100~\                                    UD~10~, UD~max~\
  PV~200~     UD~10~, UD~max~, RD~min~, RD~max~, RD~m~, RD~10~, RV~100~   UD~m~, UV~100~
  -----------------------------------------------------------------------------------------------

Abbreviations: T -- tumor stage according to TNM classification, i-PSA -- initial level of prostate specific antigen (before treatment), GS -- Gleason score, Vol -- prostate volume, NN -- number of implanted needles, P -- prostatic, U -- urethral, R -- Rectal, D~min~ -- minimal dose in treated volume, D~max~ -- maximal dose, D~m~ -- mean dose, D~90~ -- the percentage of prescribed dose delivered to 90% of treated volume, D~10~ -- the percentage of the organ at risk receiving 10% of prescribed dose; V~100~, V~200~ -- the percentage of treated volume receiving 100 and 200% of prescribed dose, respectively

Discussion {#sec4}
==========

Demanes *et al*. \[[@cit0001]\] reported excellent target coverage with D~90~ between 105% and 113% of the prescribed dose, Kini *et al*. \[[@cit0014]\] reached mean D~90~ of 97% and our median D~90~ was 91.8%. Some of our treatment plans were suboptimal, although the high single dose of 15 Gy was prescribed to CTV1 (prostate capsule) in contrast to CTV2 (peripheral zone) \[[@cit0004], [@cit0015]\] or CTV3 (tumor volume) \[[@cit0016]\]. It appears that differences came from various descriptions of the target and the method of 100% prescribed isodose normalization. Furthermore, the data is derived from the first set of implants used in the department which is also the cause of worse results. In the first year after introducing the procedure, the implantation technique has improved, in concordance with Lee *et al*. \[[@cit0017]\] and Merric *et al*. \[[@cit0018]\] who have reported their data about learning curve. The study results indicate that in the group of older patients one can expect relatively more difficulties in achieving good quality implants. It is due to the fact that older patients are more likely to be diagnosed with lower T stage, which results in smaller volume of the prostate. The small volume determines small amount of needles to be used for implantation. Akimoto *et al*. \[[@cit0007], [@cit0008]\] did not find significant correlation between the prostate volume and the number of needles implanted, but patients with 11 needles or less tended to develop higher grade genitourinary (GU) toxicity as compared with those with 12 needles or more. The GU toxicity was increased due to more inhomogenic dose distribution and hot spots as a result of small number of implanted needles. Charra-Brunaud *et al*. \[[@cit0009]\] reported that prostatic and urethral V~150~ increases whenever smaller number of needles is applied. This finding corresponds with our study, which show statistically significant relationship between small numbers of implanted needles and lower prostatic D~min~, D~90~ and V~100~, higher prostatic D~mean~ and V~200~ as well as lower urethral D~min~, D~mean~, V~100~ and higher D~max~. Nevertheless, toxicity was not an issue in this study. On the contrary, the usage of small number of needles was intentional approach of Kovács *et al*. \[[@cit0004]\]. He prescribed reference dose of 15 Gy to peripheral zone of the prostate (CTV2) with critical structures covered by low-dose areas and neglecting, to some extent, the total dose covering of the prostate. Furthermore, Borghede *et al*. \[[@cit0016]\] focused on the tumor volume (CTV3) that was defined within the prostate gland. As per Duchesne *et al*. \[[@cit0019]\], it is essential to limit the level of V~200~ to 15% of the target, in order to decrease the risk of late GU morbidity. This can be achieved in relatively large prostate glands, implanted with greater number of needles; based on our study and published data \[[@cit0001], [@cit0002], [@cit0014]\].

In addition, to improve treatment plan prepared for good implant it is advisable to use anatomy-based inverse optimization tools instead of e. g. geometrical ones \[[@cit0005], [@cit0020], [@cit0021]\]. Till date, no data was found regarding minimal prostate volume that should not be implanted and the smallest number of applicators to be used without compromising dose distribution, as well as acceptable incidence of side effects and satisfactory outcome.

Conclusions {#sec5}
===========

In conclusion, statistical analysis revealed significant correlation between age, T stage, prostate volume and number of needles used for the implant and increased prostatic D~90~ and V~100~, decreased V~200~. Amongst prognostic factors only the age was related to increased urethral D~10~ and D~max~. No relationship was found between any prognostic factor and rectal wall DVH parameters. In other words, increased prostate volume with improved D~90~ and larger number of implanted needles results in better target coverage (higher value of V~100~), better dose distribution (less hot-spots with lower value of V~200~) and decreased dose delivered to the urethra (lower urethral D~10~ and D~max~). No evident influence on rectal wall was identified. Further investigation with close follow-up should give an answer whether the above arguments corresponds with morbidity and outcome.
